AngioSoma, Inc. (OTC: SOAN) Announces Completion of Products for Market
HOUSTON -- February 5, 2018
We are pleased to announce we are launching a line of supplements under our
Somaceuticals^TM common identity to be marketed on our upcoming website to be
named soma-ceuticals.com. Our supplements cover three industry segments:
nutraceuticals, cosmeceuticals, and pharmaceuticals.
Nutraceuticals lead off with StemStrength^TM, ^ an all-natural stimulant for
accelerated muscle and tissue development and RockOn^TM, a potent libido
complex tonic for male and female usage, containing popular ingredients for
Cosmeceuticals include three products:
Rapid Wrinkle Reducer: a skin-smoothing serum gentle enough for everyday use.
Instant results from plant extracts help reduce the appearance of fine lines
and wrinkles and help to combat the appearance of aging skin.
Powerful Peptide Eye Serum: helps to reduce the appearance of eye bags, dark
circles, and puffy eyes by relieving the accumulation of fluids and increasing
the firmness around your eyes.
Collagen Anti-Aging Crème: nourishes and protects skin while encouraging skin
cell renewal. It supports elastin and collagen production, which promotes skin
moisture, elasticity, and thickness. It also has a healing effect on troubled
or damaged skin areas.
Our lead pharmaceutical drug candidate is Liprostin^TM for improving the
effectiveness of current standard-of-care treatments related to endovascular
interventions in the treatment of peripheral artery disease (PAD).
Liprostin^TM has completed FDA Phase I and three Phase II clinical trials, and
we are evaluating several contract research organizations ('CRO') for
completion of our U.S. Food and Drug Administration ('FDA') protocol for Phase
ABOUT ANGIOSOMA, INC.
AngioSoma, Inc. (http://www.angiosoma.com), a Nevada corporation based in
Houston, Texas, is dedicated to improving the mental and physical wellbeing of
men and women. To accomplish that purpose, we are launching a line of
supplements under our Somaceuticals^TM common identity. Our supplements cover
three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals.
NOTICE REGARDING FORWARD LOOKING STATEMENTS
Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words “believes,” “expects,” “anticipate” or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the company to differ materially from those expressed or
implied by such forward-looking statements.
View source version on businesswire.com:
AngioSoma, Inc. Announces Completion of Products for Market